Ladenburg analyst Aydin Huseynov raised the firm’s price target on Compass Therapeutics (CMPX) to $7 from $5 and keeps a Buy rating on the shares post the Q3 report. The firm notes growing optimism around CTX-009.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter